Abstract 120P
Background
Cetuximab (Cet) plus chemotherapy (CT) has been approved as preferred first-line (1L) treatment for left-sided (LS) metastatic colorectal cancer (mCRC) with wild-type (wt) RAS/BRAF gene. However, it remains uncertain whether Cet is beneficial as maintenance therapy after 1L treatment. This study aimed to investigate the clinical outcomes for maintenance therapy in pts with LS RAS/BRAF wt mCRC who responded to 1L Cet plus CT.
Methods
We performed a retrospective review of pts with LS RAS/BRAF wt mCRC who had disease controlled (CR, PR or SD) after 6 cycles of Cet based induction therapy from JAN 2018 to JUN 2022 at HuNan Cancer Hospital. The 1L regimen consists of Cet plus mFOLFOX6 or FOLFIRI, based on pts selection, followed by maintenance therapy with Cetuximab with or without chemotherapy (cohort A) or chemotherapy alone (cohort B). Death data were obtained from the government's death registry. Kaplan-Meier methods were employed to describe overall survival (OS) and progression-free survival (PFS).
Results
A total of 125 pts were included in this study, with 72 (57.6%) in cohort A and 53 (42.4%) in cohort B. The median age was 58 years (range: 23-76), and 86 (68.8%) were male. The most common site of metastasis was the liver (90 patients, 72.0%). During a median follow-up of 32.6 m, the median OS from the start of 1L therapy was significantly longer in cohort A (46.4 m, 95% CI 40.1-NA) than in cohort B (31.1 m, 95% CI 27.6-38.0; p < 0.0001). Similarly, cohort A (14.2 m, 95% CI 12.4-17.0) had a significantly longer median PFS than cohort B (11.0 m, 95% CI 9.6-11.7; p=0.021). The Cox proportional hazards model, after adjusting for age, sex, primary tumor location, metastatic site, and whether the primary tumor and metastases were resected or not, showed that compared with cohort B, cohort A was associated with a statistically significant longer OS (HR 0.43, 95% CI 0.25-0.73) and a longer PFS, although the difference was not statistically significant (HR 0.70, 95% CI 0.44-1.12).
Conclusions
Maintenance therapy with Cet can significantly improve OS in pts with LS RAS/BRAF wt mCRC and lead to a clinically meaningful improvement in PFS, although the statistical difference was not reached.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer
Presenter: Sungmin Kang
Session: Poster Display
Resources:
Abstract
40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Presenter: Jia Wern Pan
Session: Poster Display
Resources:
Abstract
41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome
Presenter: Sonya Park
Session: Poster Display
Resources:
Abstract
42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling
Presenter: Jisun Kim
Session: Poster Display
Resources:
Abstract
43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Presenter: Marco Wijaya
Session: Poster Display
Resources:
Abstract
44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
Presenter: Amrith Patel
Session: Poster Display
Resources:
Abstract
45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Presenter: Tanuma Mistry
Session: Poster Display
Resources:
Abstract
47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients
Presenter: Byshetty Rajendar
Session: Poster Display
Resources:
Abstract